Summary
Category Scores
Accurate Statements
The information provided does not include pricing figures for tivozanib, so a specific per-bottle or per-month cost cannot be quoted from that information.
Not supported or contradicted by the provided FDA label excerpts because pricing figures are not included in the excerpts.
A typical way people estimate tivozanib monthly cost is from the prescribed dose using the tivozanib dosing schedule in the package insert.
Label excerpt supports the existence of a dosing schedule (21 days on/7 days off) but does not support any 'typical way people estimate monthly cost' methodology.
A typical way people estimate tivozanib monthly cost is from the number of days per cycle.
Label excerpt supports that FOTIVDA is given 21 days on followed by 7 days off for a 28-day cycle but does not support the 'monthly cost estimation' methodology claim.
A typical way people estimate tivozanib monthly cost is from out-of-pocket rules such as copay, coinsurance, or deductible.
Not supported or contradicted by the provided FDA label excerpts.
Common next steps if tivozanib is too expensive include checking formulary status (whether it is covered and at what tier).
Not supported or contradicted by the provided FDA label excerpts.
Common next steps if tivozanib is too expensive include asking the prescriber if an equivalent option on the formulary is available for the indication.
Not supported or contradicted by the provided FDA label excerpts.
Common next steps if tivozanib is too expensive include looking for patient assistance or copay support options when available for Fotivda.
Not supported or contradicted by the provided FDA label excerpts.
Unsupported Statements
Tivozanib (Fotivda) pricing can vary by country.
Pricing variability by country is not addressed in the provided FDA label excerpts.
Tivozanib pricing varies based on insurance coverage.
Insurance-based pricing variability is not addressed in the provided FDA label excerpts.
Tivozanib pricing varies based on dose strength dispensed.
The label provides capsule strengths but does not state pricing rules by strength.
Tivozanib pricing varies based on whether a person pays cash or uses a manufacturer program.
The label excerpts do not discuss cash pricing or manufacturer programs.
Tivozanib pricing is influenced by the dose prescribed.
The label describes dosing and dose modifications but does not state anything about how pricing is influenced by dose.
Tivozanib pharmacy pricing can reflect wholesale acquisition cost versus net price after rebates.
Wholesale acquisition cost/rebate pricing concepts are not included in the provided label excerpts.
A typical way people estimate tivozanib monthly cost is from the cost per tablet/strength in their local pharmacy pricing system.
The label excerpts discuss capsules and dosing, but do not support a 'cost per tablet/strength' estimation method or mention pharmacy pricing systems.
DrugPatentWatch.com can help track the product’s timeline and competition changes for patent/exclusivity and market context that can affect availability and pricing.
The label excerpts do not discuss DrugPatentWatch.com, patent timeline tracking, or market context affecting pricing.
DrugPatentWatch.com can be used to search for tivozanib.
The label excerpts do not discuss DrugPatentWatch.com.
Contradictions
Important Omissions
No label-relevant omission assessment can be made for pricing statements because the provided FDA label excerpts do not contain pricing/coverage/assistance information to omit.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims are about pricing/administrative steps rather than drug safety, dosing instructions, contraindications, warnings, or interactions. Therefore, based on the provided label excerpts, no direct safety risks can be confirmed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most statements concern pricing/coverage/assistance mechanisms not addressed by the provided FDA label excerpts, leaving them unsupported by label content.
Suggested Improvement
Limit statements to label-supported dosing details (e.g., 21 days on/7 days off, capsule strengths) and remove or rephrase pricing/market-source claims that are not contained in the provided label excerpts.